These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 31693582)

  • 1. Vascular malformations syndromes: an update.
    Martinez-Lopez A; Salvador-Rodriguez L; Montero-Vilchez T; Molina-Leyva A; Tercedor-Sanchez J; Arias-Santiago S
    Curr Opin Pediatr; 2019 Dec; 31(6):747-753. PubMed ID: 31693582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [PIK3CA-related overgrowth syndrome (PROS)].
    Venot Q; Canaud G
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S155-S156. PubMed ID: 28577738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CLOVES syndrome: review of a PIK3CA-related overgrowth spectrum (PROS).
    Martinez-Lopez A; Blasco-Morente G; Perez-Lopez I; Herrera-Garcia JD; Luque-Valenzuela M; Sanchez-Cano D; Lopez-Gutierrez JC; Ruiz-Villaverde R; Tercedor-Sanchez J
    Clin Genet; 2017 Jan; 91(1):14-21. PubMed ID: 27426476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Klippel-Trenaunay syndrome belongs to the PIK3CA-related overgrowth spectrum (PROS).
    Vahidnezhad H; Youssefian L; Uitto J
    Exp Dermatol; 2016 Jan; 25(1):17-9. PubMed ID: 26268729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overgrowth Syndromes Caused by Somatic Variants in the Phosphatidylinositol 3-Kinase/AKT/Mammalian Target of Rapamycin Pathway.
    Akgumus G; Chang F; Li MM
    J Mol Diagn; 2017 Jul; 19(4):487-497. PubMed ID: 28502730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway.
    Yan W; Zhang B; Wang H; Mo R; Jiang X; Qin W; Ma L; Lin Z
    Hereditas; 2021 Jun; 158(1):18. PubMed ID: 34074347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIK3CA vascular overgrowth syndromes: an update.
    Hughes M; Hao M; Luu M
    Curr Opin Pediatr; 2020 Aug; 32(4):539-546. PubMed ID: 32692051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Diagnosis of Mosaic Overgrowth Syndromes Using a Custom-Designed Next-Generation Sequencing Panel.
    Chang F; Liu L; Fang E; Zhang G; Chen T; Cao K; Li Y; Li MM
    J Mol Diagn; 2017 Jul; 19(4):613-624. PubMed ID: 28502725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum.
    Keppler-Noreuil KM; Sapp JC; Lindhurst MJ; Parker VE; Blumhorst C; Darling T; Tosi LL; Huson SM; Whitehouse RW; Jakkula E; Grant I; Balasubramanian M; Chandler KE; Fraser JL; Gucev Z; Crow YJ; Brennan LM; Clark R; Sellars EA; Pena LD; Krishnamurty V; Shuen A; Braverman N; Cunningham ML; Sutton VR; Tasic V; Graham JM; Geer J; Henderson A; Semple RK; Biesecker LG
    Am J Med Genet A; 2014 Jul; 164A(7):1713-33. PubMed ID: 24782230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterization of 13 patients with PIK3CA-related overgrowth spectrum using a targeted deep sequencing approach.
    de Kock L; Cuillerier A; Gillespie M; Couse M; Hartley T; Mears W; Bernier FP; Chudley AE; Frosk P; Nikkel SM; Innes AM; Lauzon J; Thomas M; Guerin A; Armour CM; Weksberg R; Scott JN; Watkins D; Harvey S; Cytrynbaum C; ; Kernohan KD; Boycott KM
    Am J Med Genet A; 2024 Mar; 194(3):e63466. PubMed ID: 37949664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prenatal diagnosis of CLOVES syndrome confirmed by detection of a mosaic PIK3CA mutation in cultured amniocytes.
    Emrick LT; Murphy L; Shamshirsaz AA; Ruano R; Cassady CI; Liu L; Chang F; Sutton VR; Li M; Van den Veyver IB
    Am J Med Genet A; 2014 Oct; 164A(10):2633-7. PubMed ID: 25044986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpelisib to treat CLOVES syndrome, a member of the PIK3CA-related overgrowth syndrome spectrum.
    Garreta Fontelles G; Pardo Pastor J; Grande Moreillo C
    Br J Clin Pharmacol; 2022 Aug; 88(8):3891-3895. PubMed ID: 35146800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombosis risk factors in PIK3CA-related overgrowth spectrum and Proteus syndrome.
    Keppler-Noreuil KM; Lozier J; Oden N; Taneja A; Burton-Akright J; Sapp JC; Biesecker LG
    Am J Med Genet C Semin Med Genet; 2019 Dec; 181(4):571-581. PubMed ID: 31490637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.
    Keppler-Noreuil KM; Rios JJ; Parker VE; Semple RK; Lindhurst MJ; Sapp JC; Alomari A; Ezaki M; Dobyns W; Biesecker LG
    Am J Med Genet A; 2015 Feb; 167A(2):287-95. PubMed ID: 25557259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies.
    Keppler-Noreuil KM; Parker VE; Darling TN; Martinez-Agosto JA
    Am J Med Genet C Semin Med Genet; 2016 Dec; 172(4):402-421. PubMed ID: 27860216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and Genetic Aspects of the Segmental Overgrowth Spectrum Due to Somatic Mutations in PIK3CA.
    Kang HC; Baek ST; Song S; Gleeson JG
    J Pediatr; 2015 Nov; 167(5):957-62. PubMed ID: 26340871
    [No Abstract]   [Full Text] [Related]  

  • 17. Segmental overgrowth syndrome due to an activating PIK3CA mutation identified in affected muscle tissue by exome sequencing.
    Rasmussen M; Sunde L; Weigert KP; Bogaard PW; Lildballe DL
    Am J Med Genet A; 2014 May; 164A(5):1318-21. PubMed ID: 24665065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-related overgrowth spectrum: A brief report.
    Denorme P; Morren MA; Hollants S; Spaepen M; Suaer K; Zutterman N; Labarque V; Legius E; Brems H
    Pediatr Dermatol; 2018 May; 35(3):e186-e188. PubMed ID: 29493003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
    Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
    Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA.
    Luks VL; Kamitaki N; Vivero MP; Uller W; Rab R; Bovée JV; Rialon KL; Guevara CJ; Alomari AI; Greene AK; Fishman SJ; Kozakewich HP; Maclellan RA; Mulliken JB; Rahbar R; Spencer SA; Trenor CC; Upton J; Zurakowski D; Perkins JA; Kirsh A; Bennett JT; Dobyns WB; Kurek KC; Warman ML; McCarroll SA; Murillo R
    J Pediatr; 2015 Apr; 166(4):1048-54.e1-5. PubMed ID: 25681199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.